Eli Lilly rose 0.7% in early Friday trading. The company said that in a phase III clinical trial, orforglipron once a day helped maintain previous weight loss effects after patients switched from injectable drugs WegoVy and ZepBound; the drug has submitted an FDA application and is eligible for priority review.

Zhitongcaijing · 1d ago
Eli Lilly rose 0.7% in early Friday trading. The company said that in a phase III clinical trial, orforglipron once a day helped maintain previous weight loss effects after patients switched from injectable drugs WegoVy and ZepBound; the drug has submitted an FDA application and is eligible for priority review.